ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 2094 • ACR Convergence 2024

    Cross-sectional Associations of Radiographic Multiple Joint Osteoarthritis and Pain with Demographic and Clinical Characteristics: Design of a Multi-modal Study in Human and Pet Dogs

    Liubov Arbeeva1, Kelly Johnson2, Serena Savage-Guin3, Tessa Walker2, Masataka Enomoto4, Christina Stevens4, Milja Koskinen4, Tracey Cole4, Savannah Aker4, Connor Thonen-Fleck4, Richard Loeser5, Jordan Renner2, Duncan Lascelles6, Yvonne Golightly7 and Amanda Nelson8, 1University of North Carolina, Chapel Hill, Carrboro, NC, 2Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill,, Chapel Hill, NC, 4Translational Research in Pain and Comparative Pain Research and Education Center, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 5University of North Carolina, Chapel Hill, NC, 6North Carolina State University, Raleigh, NC, 7University of Nebraska Medical Center, Omaha, NE, 8University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Multiple joint osteoarthritis (MJOA) is a progressive, highly prevalent disease affecting millions of Americans and as well as pet dogs. This preliminary analysis sought…
  • Abstract Number: 2338 • ACR Convergence 2024

    TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis

    Lenche Kostadinova1, Brigid Wilson2, Hinnah Siddiqui2, Sara Behrens3, Angela Gupta4, Megan O'Mara3, Vicky Nahra5, Mahesha Makandura6, Shahdi Malakooti7, Maya Mattar8, David A Zidar1 and Donald D Anthony9, 1Louis Stokes VA Medical Center, cleveland, 2VA Northeast Ohio Healthcare System, Cleveland, 3CWRU, Cleveland, 4Brigham and Women's Faulkner Hospital, Rheumatology Center, Jamaica Plain, 5University Hospitals Cleveland Medical Center, Cleveland, 6Henri Ford Medical Center, Detroit, 7MetroHealth at Case Western Reserve University, Cleveland, 8Louis Stokes VA medical Center, Mayfield Heights, OH, 9Louis Stokes VA Medical Center/Metro Health, Cleveland

    Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
  • Abstract Number: 2536 • ACR Convergence 2024

    Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium

    Kevin Bu1, Rebecca Blank2, Adam Cantor1, Alba Boix-Amoros3, Jose Scher4 and Jose Clemente1, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), 1Icahn School of Medicine at Mount Sinai, New York, NY, 2NYU, New York, NY, 3Icahn School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY

    Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
  • Abstract Number: 0098 • ACR Convergence 2024

    Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus

    Marina Barguil Macedo1, Jorge Armando Gonzalez-Chapa1, Anders Bengtsson2, Iva Gunnarsson3, Elisabet Svenungsson4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Lund University, Lund, Sweden, 3Karolinska Institute, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
  • Abstract Number: 0462 • ACR Convergence 2024

    Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee1, Carlos Hunter1, Punyasha Roul2, Joshua Baker3, grant Cannon4, Beth Wallace5, Paul Monach6, Andreas Reimold7, Gail Kerr8, Isaac Smith9, John Richards10, Katherine Wysham11, Gary Kunkel12, Iris Lee13, Daniel Anderson14, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3University of Pennsylvania, Philadelphia, PA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 6VA Boston Healthcare System, Boston, MA, 7Dallas VA Medical Center, Dallas, TX, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9Duke University Hospital, Durham, NC, 10Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 11VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 12University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 13Washington University in St Louis, Saint Louis, MO, 14University of Nebraska Medical Center, Durham, NC

    Background/Purpose: Endothelial dysfunction, leading to myocardial inflammation and dysfunction, may drive a heightened risk of heart failure (HF) in people with rheumatoid arthritis (RA). Circulating…
  • Abstract Number: 0574 • ACR Convergence 2024

    14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study

    Anthony Marotta1, Walter Maksymowych2, Stephanie Wichuk2 and Navneet Sidhu1, 1Augurex Life Sciences Corp, Vancouver, BC, Canada, 2University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Diagnosis of axial spondyloarthritis (AxSpA) is challenging and often delayed primarily due to the lack of sensitive and specific markers needed for accurate and…
  • Abstract Number: 0695 • ACR Convergence 2024

    Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort

    Stefano Di Donato1, Marco Minerba2, Enrico De Lorenzis3, Collette Hartley4, Lesley-Anne Bissell5, Rebecca Ross6 and Francesco Del Galdo4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2Campus Bio-Medico University of Rome, Taranto, United Kingdom, 3Catholic University of the Sacred Heart, Roma, Rome, Italy, 4University of Leeds, Leeds, United Kingdom, 5Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
  • Abstract Number: 0838 • ACR Convergence 2024

    The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS

    Kavya Sugur1, Emily Chong1, Srilakshmi Yalavarthi2, Katarina Kmetova3, Lyndsay Kluge1, Wenying Liang2, Cyrus Sarosh4, NaveenKumar Somanathapura K2, Jacqueline Madison2, Ajay Tambralli2, Jason Knight2 and Yu Zuo2, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 4University of Michigan, Temperance, MI

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
  • Abstract Number: 0964 • ACR Convergence 2024

    Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model

    Maithri Aspari1, Voon Ong2, Klaus Soendergaard3, Esben Naeser4, Malene Hvid4, Angela Tam5, Shiwen Xu5, Christopher Denton6, David Abraham7, Bent Deleuran1 and Stinne Greisen8, 1Aarhus University, Aarhus, Denmark, 2University College London, London, England, United Kingdom, 3Aarhus University Hospital, Aarhus, Denmark, 4AARHUS UNIVERSITET, AARHUS C, Denmark, 5University College London, London, United Kingdom, 6University College London, Northwood, United Kingdom, 7UCL, London, United Kingdom, 8Aarhus University/Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
  • Abstract Number: 1317 • ACR Convergence 2024

    Serum (1-3)-β-D-Glucan Levels in Juvenile Idiopathic Arthritis

    Yasmine LAMROUS, Camille LEGLISE, Audrey VANRENTERGHEM, Taieb CHOUAKI and Djamal-Dine DJEDDI, CHU AMIENS PICARDIE, AMIENS, France

    Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses the most common chronic rheumatologic manifestations in children. It results from the interplay of genetic, environmental, and infectious factors.…
  • Abstract Number: 1570 • ACR Convergence 2024

    Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung

    Sunhwa Kim1, Yingtao Bi2, Vishal Kakkar3, Rebecca Ross4 and Francesco Del Galdo3, 1AbbVie, South San Francisco, CA, 2Abbvie, Worcester, MA, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease with variable clinical presentations and progression rates. Accurate patient stratification is crucial for optimizing treatment strategies.…
  • Abstract Number: 1808 • ACR Convergence 2024

    Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients

    Paula Losada Vanegas1, Juan Antonio Villatoro-García2, Daniel Rodriguez3, Juan Camilo Diaz3, Ricardo Pineda4, Pedro Carmona-Saez5, Mauricio Rojas6 and Gloria Vasquez7, 1Universidad de Antioquia, Medellin, Antioquia, Colombia, 2GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Andalucia, Spain, 3ARTMEDICA, Medellín, Antioquia, Colombia, 4ARTMEDICA, Medellin, Antioquia, Colombia, 5GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Asturias, Spain, 6Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina. Universidad de Antioquia, Medellin, Antioquia, Colombia, 7Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina.Universidad de Antioquia, Medellin, Colombia

    Background/Purpose: Monocytes play an important role in organ damage, such as in Lupus Nephritis (LN). Although monocytes are typically considered inflammatory cells, evidence shows they…
  • Abstract Number: 2102 • ACR Convergence 2024

    Unraveling Knee Osteoarthritis Subtypes: Differential Effect of Oral Salmon Calcitonin Treatment

    Monica Hannani1, Peder Frederiksen2, Morten Karsdal2, Asger Reinstrup Bihlet3, Jaume Bacardit4, Anne-Christine Bay-Jensen2 and Christian Thudium2, 1Nordic Bioscience & University of Copenhagen, Herlev, Denmark, 2Nordic Bioscience, Herlev, Denmark, 3NBCD A/S, Soeborg, Denmark, 4School of Computing, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Osteoarthritis (OA) patients are to this day left without effective treatment options. Despite different etiologies, trials designs do not account for the substantial heterogeneity…
  • Abstract Number: 2357 • ACR Convergence 2024

    Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies

    Joseph Merola1, Alexis Ogdie2, Arthur Kavanaugh3, Evan Leibowitz4, Emmanouil Rampakakis5, Ryan Funk6, Francois Nantel7, Frederic Lavie8, Katelyn Rowland9 and Enrique R. Soriano10, 1UT Southwestern Medical Center, Newton, MA, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3University of California San Diego, La Jolla, CA, 4Janssen Scientific Affairs, LLC, Fair Lawn, NJ, 5McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 6Johnson & Johnson Innovative Medicine, Long Grove, IL, 7Nantel MedSci Consult, Montreal, QC, Canada, 8Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 9Janssen Pharmaceuticals, Horsham, PA, 10Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: Psoriatic disease (PsD) is associated with an increased risk of cardiovascular (CV) disease. Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of systemic inflammation; NLR ≥2.5…
  • Abstract Number: 2561 • ACR Convergence 2024

    Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

    Natalie McCormick1, Amit Joshi2, Robert Terkeltaub3, Tony Merriman4, Matthew Nayor5, Chio Yokose6 and Hyon K. Choi7, 1Massachusetts General Hospital, Boston, MA, 2Channing Division of Network Medicine, Boston, MA, 3Retired, San Diego, CA, 4University of Alabama at Birmingham, Homewood, AL, 5Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 6Massachusetts General Hospital, Waltham, MA, 7Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout.  A previous cross-sectional study of pre-existing gout (n=330…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology